Latest News

Retirees will appreciate the bump, but is it enough?

New digital asset treasury companies, no matter how big they become, are unlikely to boost the price of XRP.

enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle

Micron has a long history of volatility. What does the current drawdown mean for investors?

Nike is still recovering from a strategic decision that backfired a few years ago.

Investors are concerned about increasing dilution as the management makes another acquisition.

SoFi's business is inversely correlated to interest rates.

Bond buyers now want almost 15% to lend to a cloud company the AI chip leader has billions invested in. Should its shareholders worry?

Anthropic is on the upswing, while OpenAI is struggling.

One trades at 11x forward earnings with $4.6 billion in operating cash flow; the other is nearly debt-free with 23% net margins.

The AI trade is showing signs of fatigue. Is it justified?

Since 1950, 54 past calm streaks like this have a full year of results.

Here's why Brookfield's ability to keep finding high-quality investment opportunities makes it one of the best TSX stocks to buy and hold.

A proven drawdown strategy can help avoid a big tax hit on your RRSP in retirement.

Timelines may not mean much to Tesla, but they do to shareholders.

With a 5.6% annualized yield, growing rental income, and monthly payouts, this Canadian REIT could help turn your retirement portfolio into a reliable income source.

How early liquidity decisions can quietly erase life-changing upside from your portfolio.

J.B. Hunt Transport Services (NASDAQ:JBHT) reported third-quarter revenue growth and modest gains in operating income and earnings per share as strong demand across its transportation services was partly offset by higher driver-related, fuel, claims and medical costs. On a GAAP basis, total revenue

PDS Biotechnology (NASDAQ:PDSB) outlined plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases, following discussions with the U.S. Food and Drug Administration and clinical findings from a Nationa

Here’s why this Canadian dividend stock is worth considering if you want monthly income and long-term growth without locking your money away.

The Hamilton Enhanced Canadian Covered Call ETF (TSX:HDIV) looks like a stellar passive income booster for those who can handle the added (managable) risks.

The $1.7 retirement target based on a survey has become a perception and not an official benchmark.

Data centers need massive amounts of power, and this reliable dividend stock is capitalizing on that demand.

Can you live off dividends? See how much you would need to invest, what BNS, CU, and ZWC could pay, and where the income math falls short.

This stock has delivered annual dividend increases for more than 30 years.